{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A3+Expansion&page=2",
    "query": {
      "intervention": "A3 Expansion",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A3+Expansion&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T21:01:27.320Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03429101",
      "title": "A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Poziotinib",
          "type": "DRUG"
        },
        {
          "name": "T-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2018-07-13",
      "completion_date": "2019-04-17",
      "has_results": false,
      "last_update_posted_date": "2021-01-15",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Glendale, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03429101"
    },
    {
      "nct_id": "NCT05669430",
      "title": "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Refractory Cancer",
        "Endometrial Carcinoma (EC)",
        "Squamous Head and Neck Carcinoma",
        "pMMR/MSS Adenocarcinoma of the Colon or Rectum",
        "Cutaneous Melanoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "GV20-0251",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GV20-0251 and Pembrolizumab [KEYTRUDA®]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GV20 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2023-03-23",
      "completion_date": "2027-09-05",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05669430"
    },
    {
      "nct_id": "NCT04384146",
      "title": "Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclical Hypofractionated Palliative Radiation (Quad Shot)",
          "type": "RADIATION"
        },
        {
          "name": "EORTC QLQ-C30 questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2020-05-07",
      "completion_date": "2026-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04384146"
    },
    {
      "nct_id": "NCT04104672",
      "title": "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AB680",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2019-11-06",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • St Louis, Missouri • New York, New York + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04104672"
    },
    {
      "nct_id": "NCT01920061",
      "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "PF-05212384 (gedatolisib)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Dacomitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2013-09-10",
      "completion_date": "2020-01-08",
      "has_results": true,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01920061"
    },
    {
      "nct_id": "NCT02313272",
      "title": "Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Stereotactic Irradiation (HFSRT)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-07-28",
      "completion_date": "2021-08-09",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02313272"
    },
    {
      "nct_id": "NCT03440437",
      "title": "A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "FS118",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "invoX Pharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-04-16",
      "completion_date": "2024-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03440437"
    },
    {
      "nct_id": "NCT03492125",
      "title": "A Study Of The Selective PKC-β Inhibitor MS- 553",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Aggressive Lymphoma"
      ],
      "interventions": [
        {
          "name": "MS-553",
          "type": "DRUG"
        },
        {
          "name": "acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MingSight Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2018-05-25",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-10",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492125"
    },
    {
      "nct_id": "NCT04969835",
      "title": "A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Salivary Gland Tumor",
        "Urothelial Carcinoma",
        "Ovarian Carcinoma",
        "Breast Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "AVA6000",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avacta Life Sciences Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2021-07-16",
      "completion_date": "2026-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 3,
      "location_summary": "New York, New York • Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969835"
    },
    {
      "nct_id": "NCT02386826",
      "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Gliosarcoma",
        "Colorectal Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "INC280",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2015-09-22",
      "completion_date": "2023-08-23",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-09-29T21:01:27.320Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Kansas City, Missouri + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02386826"
    }
  ]
}